Evidence map›Paper›PMID 40058857›Full record

ArticleInternal medicine (Tokyo, Japan)2025

Double-seropositive Myasthenia Gravis Following COVID-19.

Yuki Hiraoka, Yasushi Hosoi, Takuya Tsubata, Miharu Yanagida, Yusuke Otake, Michiko Ito

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yuki HiraokaDepartment of Respiratory Medicine, Hamamatsu Medical Center, Japan.
Yasushi HosoiDepartment of Neurology, Hamamatsu Medical Center, Japan.
Takuya TsubataDepartment of Neurology, Hamamatsu Medical Center, Japan.
Miharu YanagidaDepartment of Neurology, Hamamatsu Medical Center, Japan.
Yusuke OtakeDepartment of Neurology, Hamamatsu Medical Center, Japan.
Michiko ItoDepartment of Neurology, Hamamatsu Medical Center, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myasthenia gravis (MG) is an autoimmune disease characterized by muscle weakness caused by antibodies targeting acetylcholine receptors (AChRs) or muscle-specific kinase (MuSK). Double-seropositive MG (DSP-MG) caused by both antibodies is rare. We herein report a 78-year-old woman who developed DSP-MG after coronavirus disease 2019 infection. She presented with neck muscle fatigue and upper-limb weakness. Elevated levels of anti-AChR and anti-MuSK antibodies were detected. The patient responded well to the immunosuppressive therapy. This case highlights the potential for various autoimmune neurological conditions post-viral infection and the significance of prompt recognition and treatment.

Indexed as

AutoantibodiesCOVID-19Myasthenia GravisAgedFemaleHumansImmunosuppressive AgentsReceptor Protein-Tyrosine KinasesReceptors, CholinergicSARS-CoV-2AutoantibodiesImmunosuppressive AgentsMUSK protein, humanReceptor Protein-Tyrosine KinasesReceptors, CholinergicCOVID-19double seropositivemyasthenia gravisSARS-CoV-2 virus

Identifiers

PMID40058857
PMCPMC12183409

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.